Mirum Pharmaceuticals (MIRM) Total Current Liabilities (2018 - 2026)

Mirum Pharmaceuticals' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $272.8 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 113.85% year-over-year to $272.8 million; the TTM figure through Mar 2026 stood at $272.8 million (up 113.85% YoY), while the FY2025 annual figure was $205.8 million, up 62.62% from the prior year.
• Total Current Liabilities was $272.8 million for Q1 2026 at Mirum Pharmaceuticals, up from $205.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $272.8 million in Q1 2026 to a low of $34.6 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $108.0 million across 5 years, with a median of $105.9 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities retreated 1.34% in 2022, then soared 116.84% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $64.7 million in 2022, then surged by 34.51% to $87.1 million in 2023, then soared by 45.35% to $126.6 million in 2024, then soared by 62.62% to $205.8 million in 2025, then soared by 32.57% to $272.8 million in 2026.
• The last three Total Current Liabilities figures came in at $272.8 million (Q1 2026), $205.8 million (Q4 2025), and $160.4 million (Q3 2025), per Business Quant data.